TRAIL-induced apoptosis of hepatocellular carcinoma cells isaugmented by targeted therapies | Zendy

Bruno Christian Koehler | Zendy; Toni Urbanik | Zendy; Binje Vick | Zendy; Regina Boger | Zendy; S. Heeger | Zendy; Peter R. Galle | Zendy; Marcus Schuchmann | Zendy; Henning SchulzeBergkamen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

TRAIL-induced apoptosis of hepatocellular carcinoma cells isaugmented by targeted therapies

Author(s) -

Bruno Christian Koehler,

Toni Urbanik,

Binje Vick,

Regina Boger,

S. Heeger,

Peter R. Galle,

Marcus Schuchmann,

Henning SchulzeBergkamen

Publication year - 2009

Publication title -

world journal of gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.427

H-Index - 155

eISSN - 2219-2840

pISSN - 1007-9327

DOI - 10.3748/wjg.15.5924

Subject(s) - apoptosis , sorafenib , cancer research , kinase , flow cytometry , pi3k/akt/mtor pathway , biology , microbiology and biotechnology , chemistry , hepatocellular carcinoma , biochemistry

To analyze the effect of chemotherapeutic drugs and specific kinase inhibitors, in combination with the death receptor ligand tumor necrosis factor-related apoptosis inducing ligand (TRAIL), on overcoming TRAIL resistance in hepatocellular carcinoma (HCC) and to study the efficacy of agonistic TRAIL antibodies, as well as the commitment of antiapoptotic BCL-2 proteins, in TRAIL-induced apoptosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research